Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Total revenue	$ 23,028	$ 135,082	$ 19,886
Operating expenses:
Research and development	82,701	107,851	113,820
General and administrative	29,410	21,846	17,745
Total operating expenses	112,111	129,697	131,565
Operating (loss) income	(89,083)	5,385	(111,679)
Other income, net	642	2,334	4,490
(Loss) income before income tax benefit	(88,441)	7,719	(107,189)
Income tax benefit	0	691	816
Net (loss) income	$ (88,441)	$ 8,410	$ (106,373)
Net (loss) income per share:
Basic	$ (1.74)	$ 0.18	$ (2.49)
Diluted	$ (1.74)	$ 0.18	$ (2.49)
Weighted average shares:
Basic	50,718,765	47,413,250	42,669,333
Diluted	50,718,765	47,915,030	42,669,333
Other comprehensive (loss) income, net of tax of $0:
Change in unrealized (losses) gains on available-for-sale marketable securities	$ (431)	$ (97)	$ 284
Total comprehensive (loss) income	(88,872)	8,313	(106,089)
License and Milestone Fees
Revenue:
Total revenue	21,223	134,439	19,746
Collaborative Revenue
Revenue:
Total revenue	706
Commercial Supply Revenue
Revenue:
Total revenue	701
Clinical Compound Revenue
Revenue:
Total revenue	$ 398	$ 643	$ 140